[
  {
    "ts": null,
    "headline": "AI Investment Is Already Huge. Google, Trump Show Much More Is Coming.",
    "summary": "Google will spend $85 billion on artificial-intelligence projects this year. Its rivals are likely to spend more.",
    "url": "https://finnhub.io/api/news?id=454cc7576b2a1798ad2a27045d63362b4cd6aa6703ead474a7de8919afa42161",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753380540,
      "headline": "AI Investment Is Already Huge. Google, Trump Show Much More Is Coming.",
      "id": 136084702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Google will spend $85 billion on artificial-intelligence projects this year. Its rivals are likely to spend more.",
      "url": "https://finnhub.io/api/news?id=454cc7576b2a1798ad2a27045d63362b4cd6aa6703ead474a7de8919afa42161"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Faces Legal Challenges Over Depo-Provera's Increased Brain Tumor Risk",
    "summary": "Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its recent share price performance. Despite reporting a 11% quarterly price movement, Pfizer's stock behavior aligns with broader market trends, which showed an 18% rise over the past year. Positive developments, such as successful trial results for XTANDI and HYMPAVZI™, contributed positively but...",
    "url": "https://finnhub.io/api/news?id=4ab132f81fc2d67ccc03a23d64f63ed0066e5859fa3844027176347ee15980c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753378087,
      "headline": "Pfizer (PFE) Faces Legal Challenges Over Depo-Provera's Increased Brain Tumor Risk",
      "id": 136085094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its recent share price performance. Despite reporting a 11% quarterly price movement, Pfizer's stock behavior aligns with broader market trends, which showed an 18% rise over the past year. Positive developments, such as successful trial results for XTANDI and HYMPAVZI™, contributed positively but...",
      "url": "https://finnhub.io/api/news?id=4ab132f81fc2d67ccc03a23d64f63ed0066e5859fa3844027176347ee15980c4"
    }
  },
  {
    "ts": null,
    "headline": "Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices",
    "summary": "The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump administration calls for the industry to cut prices.",
    "url": "https://finnhub.io/api/news?id=85d22235e76bdfb48f00a2dbf07f7e4edf9f9c127f7c5267e3dbc612394fe3b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753370160,
      "headline": "Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices",
      "id": 136068056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump administration calls for the industry to cut prices.",
      "url": "https://finnhub.io/api/news?id=85d22235e76bdfb48f00a2dbf07f7e4edf9f9c127f7c5267e3dbc612394fe3b6"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?",
    "summary": "BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.",
    "url": "https://finnhub.io/api/news?id=501be251bd192d0235da68db1b3fa692c3a327e253e929f781afa5355f5a74f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753368540,
      "headline": "Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?",
      "id": 136084964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.",
      "url": "https://finnhub.io/api/news?id=501be251bd192d0235da68db1b3fa692c3a327e253e929f781afa5355f5a74f0"
    }
  },
  {
    "ts": null,
    "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
    "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
    "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365900,
      "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
      "id": 136084782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
      "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc. ‘s share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in […]",
    "url": "https://finnhub.io/api/news?id=98dbbd5056713791a5bf82fa72d81d96d3e7cf37f6ec6653c8e84a703914f7a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753364904,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 136066211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc. ‘s share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in […]",
      "url": "https://finnhub.io/api/news?id=98dbbd5056713791a5bf82fa72d81d96d3e7cf37f6ec6653c8e84a703914f7a7"
    }
  },
  {
    "ts": null,
    "headline": "Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche",
    "summary": "The Global Selective Estrogen Receptor Degrader (SERD) Market is rapidly evolving, highlighted by key innovations like FDA-approved Orserdu and the upcoming vepdegestrant, a pioneering PROTAC-based SERD by Pfizer and Arvinas. With over 25 fulvestrant generics available, the landscape is dynamic and expanding beyond breast cancer.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trial",
    "url": "https://finnhub.io/api/news?id=0783770553bbb78149b0d106719e58e309e6ce54870efd66245ffc2094763625",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753363740,
      "headline": "Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche",
      "id": 136066212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Selective Estrogen Receptor Degrader (SERD) Market is rapidly evolving, highlighted by key innovations like FDA-approved Orserdu and the upcoming vepdegestrant, a pioneering PROTAC-based SERD by Pfizer and Arvinas. With over 25 fulvestrant generics available, the landscape is dynamic and expanding beyond breast cancer.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trial",
      "url": "https://finnhub.io/api/news?id=0783770553bbb78149b0d106719e58e309e6ce54870efd66245ffc2094763625"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Completes Licensing Agreement with 3SBio",
    "summary": "NEW YORK, July 24, 2025--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=2c00f101af5d6044424f1586c63ee6f209cc123e3d6ba9f10477bbd89a79419a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753353900,
      "headline": "Pfizer Completes Licensing Agreement with 3SBio",
      "id": 136065982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, July 24, 2025--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=2c00f101af5d6044424f1586c63ee6f209cc123e3d6ba9f10477bbd89a79419a"
    }
  },
  {
    "ts": null,
    "headline": "Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care",
    "summary": "Explore the evolving landscape of the Global Benign Breast Disease and Early Breast Cancer market from 2025-2035. Benign Breast Disease encompasses non-cancerous conditions like fibrocystic changes, manageable through non-invasive treatments. Meanwhile, Early Breast Cancer, detected in stages 0-2, benefits from advanced therapies and early intervention. Rising awareness and innovations in screening, such as 3D mammography, are propelling market growth. However, high costs of treatments and unequ",
    "url": "https://finnhub.io/api/news?id=5f4e027a5d9c175e2fc80f07e4a8b2a06778fba13bbbfcce64d8d5544219657d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753350360,
      "headline": "Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care",
      "id": 136066216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Explore the evolving landscape of the Global Benign Breast Disease and Early Breast Cancer market from 2025-2035. Benign Breast Disease encompasses non-cancerous conditions like fibrocystic changes, manageable through non-invasive treatments. Meanwhile, Early Breast Cancer, detected in stages 0-2, benefits from advanced therapies and early intervention. Rising awareness and innovations in screening, such as 3D mammography, are propelling market growth. However, high costs of treatments and unequ",
      "url": "https://finnhub.io/api/news?id=5f4e027a5d9c175e2fc80f07e4a8b2a06778fba13bbbfcce64d8d5544219657d"
    }
  },
  {
    "ts": null,
    "headline": "Biosimilars Markets Global Forecast Report 2025-2035 | Launch of Glp-1 Biosimilars, Increasing Strategic Partnerships and Collaborations, & Growing Focus on Advanced R&D Fueling Opportunities",
    "summary": "The global biosimilars market is expected to surge to USD 72.29 billion by 2035, growing at a CAGR of 7.5% from USD 35.04 billion in 2025. This growth is driven by rising awareness of biosimilar safety, favorable insurance structures, and demand for cost-effective biologics. The monoclonal antibodies segment, used in treating multiple conditions like cancer and autoimmune diseases, is anticipated to see the highest growth, fueled by patent expirations and increased adoption. The US biosimilars m",
    "url": "https://finnhub.io/api/news?id=64def7810c0561b1d40f85e02022294b5572bb506e14a91f8430d10e510af1ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753350240,
      "headline": "Biosimilars Markets Global Forecast Report 2025-2035 | Launch of Glp-1 Biosimilars, Increasing Strategic Partnerships and Collaborations, & Growing Focus on Advanced R&D Fueling Opportunities",
      "id": 136066419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global biosimilars market is expected to surge to USD 72.29 billion by 2035, growing at a CAGR of 7.5% from USD 35.04 billion in 2025. This growth is driven by rising awareness of biosimilar safety, favorable insurance structures, and demand for cost-effective biologics. The monoclonal antibodies segment, used in treating multiple conditions like cancer and autoimmune diseases, is anticipated to see the highest growth, fueled by patent expirations and increased adoption. The US biosimilars m",
      "url": "https://finnhub.io/api/news?id=64def7810c0561b1d40f85e02022294b5572bb506e14a91f8430d10e510af1ce"
    }
  },
  {
    "ts": null,
    "headline": "CNI- Is this Canadian Railway a Value Trap",
    "summary": "Shares of Canadian National Railway Co. (CNI) fell after the railway operator cut its profit growth forecast for the third year in a row. CN Rail now sees profit growing in the mid-to-high-single-digit range, down from 10-15%. The company is blaming tariff headwinds and a stronger Canadian dollar, writes Amber Kanwar, host of the In the Money with Amber Kanwar podcast.",
    "url": "https://finnhub.io/api/news?id=564d4760f4c8b3d5d0a47868dbc471ad6b6052d2701725ac3a29250d22ea279d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753333260,
      "headline": "CNI- Is this Canadian Railway a Value Trap",
      "id": 136085098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Canadian National Railway Co. (CNI) fell after the railway operator cut its profit growth forecast for the third year in a row. CN Rail now sees profit growing in the mid-to-high-single-digit range, down from 10-15%. The company is blaming tariff headwinds and a stronger Canadian dollar, writes Amber Kanwar, host of the In the Money with Amber Kanwar podcast.",
      "url": "https://finnhub.io/api/news?id=564d4760f4c8b3d5d0a47868dbc471ad6b6052d2701725ac3a29250d22ea279d"
    }
  }
]